Epic Bio, is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.
Total raised: $158M
Founded date: 2018
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.08.2026 | Series C | $90M | Angelini V... |
| 30.03.2025 | Series B | $68M | - |
Mentions in press and media 8
| Date | Title | Description |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 11.08.2026 | Epicrispr Biotechnologies Raises $90M in Series C Funding | Epicrispr Biotechnologies, a San Francisco, CA-based provider of a programmable epigenetic medicines platform, raised $90M in Series C financing. The round was led by Octagon Capital and Janus Henderson Investors with participation from Fid... |
| 11.08.2026 | Epicrispr Biotechnologies Raises $90 Million Series C To Advance Epigenetic Therapy EPI-321 | Epicrispr Biotechnologies has closed an oversubscribed $90 million Series C financing to advance EPI-321 toward pivotal clinical development for facioscapulohumeral muscular dystrophy, or FSHD. The financing was co-led by Octagon Capital an... |
| 11.08.2026 | Vaderis Therapeutics Raises $152M in Series B Funding | Vaderis Therapeutics, a Basel, Switzerland-based provider of targeted therapies for rare vascular diseases, raised $152M in Series B funding. The round was led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from ... |
| 31.03.2025 | Epicrispr Biotechnologies: A New Dawn in Genetic Therapy | Epicrispr Biotechnologies is making waves in the biotechnology sector. The company recently secured $68 million in Series B funding. This financial boost is a beacon of hope for patients suffering from facioscapulohumeral muscular dystrophy... |
| 30.03.2025 | Epicrispr Biotechnologies: $68 Million (Series B) Raised For Developing Curative Therapies | Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, announced it has secured $68 million in the first close of its Series B financing. The proceeds from the funding will support the clinical developm... |
| 26.03.2025 | Epicrispr Biotechnologies Raises $68M in Series B Funding | Epicrispr Biotechnologies, a South San Francisco, CA-based biotechnology company focused on developing curative therapies, raised $68m in the first close of its Series B financing. The round was led by Ally Bridge Group, with participation ... |
| 26.03.2025 | Epicrispr Biotechnologies Bags $68 Million Series B | SOUTH SAN FRANCISCO, CA, Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, announced it has secured $68 million in the first close of its Series B financing. >> Click here for more funding d... |